Serum salusin-? and -ß levels in patients with parkinson?s disease

Basit Öğe Kaydı
dc.authoridAlgul, Fatma Ebru/0000-0003-0318-7571
dc.contributor.authorAlgul, Fatma Ebru
dc.contributor.authorKoc, Emine
dc.contributor.authorKaya, Hatice Tosun
dc.date.accessioned2024-08-04T20:54:39Z
dc.date.available2024-08-04T20:54:39Z
dc.date.issued2024
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground The etiology of Parkinson ' s disease (PD) is not well known and there is increasing evidence that oxidative stress also plays an important role in its pathogenesis. Salusins alpha (salusin-alpha) and beta (salusin-ss) affect the central nervous system, vasculature, and kidneys to increase the inflammatory response in endothelial cells, stimulate oxidative stress, and increase monocyte-endothelial adhesion. Neuroinflammation and oxidative stress play roles in the etiopathogenesis of PD. Purpose To investigate whether salusin-alpha and -ss are related to PD and whether they are correlated with the development of atherosclerosis, body mass index, disease duration, and the Parkinson ' s Hoehn and Yahr stage. Results The low-density lipoprotein cholesterol (LDL-C), total cholesterol, and salusin-ss levels were significantly lower and age was significantly higher in Parkinson patients compared to healthy controls (p < 0.005). We found a negative linear correlation between salusin-ss and the Hoehn and Yahr stage (p < 0.001, r = -0.515) in the patients. Conclusions There was a relationship between salusin-ss and PD and a correlation between the salusin-ss levels and Parkinson's stage. A possible underlying disease mechanism is an increase in oxidative stress and decrease in neuroprotective effects due to low salusin-ss levels. Therefore, the effects of salusin-ss in treating Parkinson disease should be evaluated. Further studies are needed to understand the effects of salusin-ss treatment on preventing or slowing the course of PD.en_US
dc.identifier.doi10.1007/s10072-023-07031-0
dc.identifier.endpage590en_US
dc.identifier.issn1590-1874
dc.identifier.issn1590-3478
dc.identifier.issue2en_US
dc.identifier.pmid37668828en_US
dc.identifier.scopus2-s2.0-85169840157en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage585en_US
dc.identifier.urihttps://doi.org/10.1007/s10072-023-07031-0
dc.identifier.urihttps://hdl.handle.net/11616/101558
dc.identifier.volume45en_US
dc.identifier.wosWOS:001062736300003en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer-Verlag Italia Srlen_US
dc.relation.ispartofNeurological Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectSalusin betaen_US
dc.subjectSalusin alfaen_US
dc.subjectParkinson ' s diseaseen_US
dc.subjectParkinson stageen_US
dc.titleSerum salusin-? and -ß levels in patients with parkinson?s diseaseen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu